266. 家族性地中海熱 Disease details / Clinical trials / Drug dev / DR info

臨床試験数 : 35 / 薬物数 : 21 - (DrugBank : 7) / 標的遺伝子数 : 14 - 標的パスウェイ数 : 58

薬物、開発者（Primary Sponsor）、臨床試験情報（症例登録開始年（Enrollment year）、フェーズ、ID、実施国）
0.9% physiological saline
   University Hospital Tuebingen
      2018   Phase 2   NCT03446209   Germany
ACZ885
   Novartis Farma SpA
      2014   Phase 3   EUCTR2013-004291-35-IT   Belgium;Canada;Denmark;Finland;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Japan;Netherlands;Russian Federation;Spain;Switzerland;Turkey;United Kingdom;United States
   Novartis Farmacéutica, S.A.
      2014   Phase 3   EUCTR2013-004291-35-ES   Belgium;Canada;Denmark;Finland;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Japan;Netherlands;Russian Federation;Spain;Switzerland;Turkey;United Kingdom;United States
   Novartis Pharma Services AG
      2014   Phase 3   EUCTR2013-004291-35-NL   Belgium;Canada;Denmark;Finland;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Japan;Netherlands;Russian Federation;Spain;Switzerland;Turkey;United Kingdom;United States
      2014   Phase 3   EUCTR2013-004291-35-IE   Belgium;Canada;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Japan;Netherlands;Russian Federation;Spain;Switzerland;Turkey;United Kingdom;United States
      2014   Phase 3   EUCTR2013-004291-35-HU   Belgium;Canada;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Japan;Netherlands;Russian Federation;Spain;Switzerland;Turkey;United Kingdom;United States
      2014   Phase 3   EUCTR2013-004291-35-GR   Belgium;Canada;Denmark;Finland;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Japan;Netherlands;Russian Federation;Spain;Switzerland;Turkey;United Kingdom;United States
      2014   Phase 3   EUCTR2013-004291-35-BE   Belgium;Canada;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Japan;Netherlands;Russian Federation;Spain;Switzerland;Turkey;United Kingdom;United States
   Novartis Pharmaceuticals
      -   -   EUCTR2015-003527-57-Outside-EU/EEA   Turkey
      -   -   EUCTR2015-003522-13-Outside-EU/EEA   Israel
   Novartis pharma AG
      -   Phase 3   EUCTR2017-001678-40-Outside-EU/EEA   Japan
ACZ885, 150MG/1.0ML
   Novartis Pharma Services AG
      2014   Phase 3   EUCTR2013-004291-35-DE   Belgium;Canada;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Japan;Netherlands;Russian Federation;Spain;Switzerland;Turkey;United Kingdom;United States
Anakinra
   Assistance Publique - Hôpitaux de Paris
      2024   Phase 3   NCT06336733   France
   Beijing Childrens Hospital,Capital Medical University
      2024   Phase 4   ChiCTR2400091998   China
   Swedish Orphan Biovitrum
      2025   Phase 4   NCT06666335   -
Canakinumab
   Novartis Farma SpA
      2014   Phase 3   EUCTR2013-004291-35-IT   Belgium;Canada;Denmark;Finland;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Japan;Netherlands;Russian Federation;Spain;Switzerland;Turkey;United Kingdom;United States
   Novartis Farmacéutica, S.A.
      2014   Phase 3   EUCTR2013-004291-35-ES   Belgium;Canada;Denmark;Finland;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Japan;Netherlands;Russian Federation;Spain;Switzerland;Turkey;United Kingdom;United States
   Novartis Pharma Services AG
      2014   Phase 3   EUCTR2013-004291-35-NL   Belgium;Canada;Denmark;Finland;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Japan;Netherlands;Russian Federation;Spain;Switzerland;Turkey;United Kingdom;United States
      2014   Phase 3   EUCTR2013-004291-35-IE   Belgium;Canada;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Japan;Netherlands;Russian Federation;Spain;Switzerland;Turkey;United Kingdom;United States
      2014   Phase 3   EUCTR2013-004291-35-HU   Belgium;Canada;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Japan;Netherlands;Russian Federation;Spain;Switzerland;Turkey;United Kingdom;United States
      2014   Phase 3   EUCTR2013-004291-35-GR   Belgium;Canada;Denmark;Finland;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Japan;Netherlands;Russian Federation;Spain;Switzerland;Turkey;United Kingdom;United States
      2014   Phase 3   EUCTR2013-004291-35-DE   Belgium;Canada;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Japan;Netherlands;Russian Federation;Spain;Switzerland;Turkey;United Kingdom;United States
      2014   Phase 3   EUCTR2013-004291-35-BE   Belgium;Canada;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Japan;Netherlands;Russian Federation;Spain;Switzerland;Turkey;United Kingdom;United States
   Novartis Pharmaceuticals
      2010   Phase 2   NCT01148797   Israel
      2010   Phase 2   NCT01088880   Turkey
      -   -   EUCTR2015-003527-57-Outside-EU/EEA   Turkey
      -   -   EUCTR2015-003522-13-Outside-EU/EEA   Israel
   Novartis pharma AG
      -   Phase 3   EUCTR2017-001678-40-Outside-EU/EEA   Japan
Colchicine
   Assistance Publique - Hôpitaux de Paris
      2022   -   NCT05418686   France
   Gulhane Military Medical Academy
      2011   Phase 4   NCT02602028   Turkey
Colchicine cessation
   Rambam Health Care Campus
      2014   Phase 2   NCT02175589   Israel
Colchicine level measurement
   Sheba Medical Center
      2017   -   NCT03210610   Israel
Colchicine sprinkle capsules
   Mutual Pharmaceutical Company, Inc.
      2010   Phase 1   NCT01075906   Armenia;Israel;Turkey;United States
IL-1 trap
   National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
      2004   Phase 2   NCT00094900   United States
Ilaris
   Novartis Farma SpA
      2014   Phase 3   EUCTR2013-004291-35-IT   Belgium;Canada;Denmark;Finland;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Japan;Netherlands;Russian Federation;Spain;Switzerland;Turkey;United Kingdom;United States
   Novartis Farmacéutica, S.A.
      2014   Phase 3   EUCTR2013-004291-35-ES   Belgium;Canada;Denmark;Finland;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Japan;Netherlands;Russian Federation;Spain;Switzerland;Turkey;United Kingdom;United States
   Novartis Pharma Services AG
      2014   Phase 3   EUCTR2013-004291-35-NL   Belgium;Canada;Denmark;Finland;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Japan;Netherlands;Russian Federation;Spain;Switzerland;Turkey;United Kingdom;United States
      2014   Phase 3   EUCTR2013-004291-35-DE   Belgium;Canada;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Japan;Netherlands;Russian Federation;Spain;Switzerland;Turkey;United Kingdom;United States
   Novartis Pharmaceuticals
      2025   -   NCT06838143   -
      -   -   EUCTR2015-003527-57-Outside-EU/EEA   Turkey
      -   -   EUCTR2015-003522-13-Outside-EU/EEA   Israel
   Novartis pharma AG
      -   Phase 3   EUCTR2017-001678-40-Outside-EU/EEA   Japan
INN-tocilizumab
   University Hospital Tuebingen
      2017   Phase 2   EUCTR2016-004505-13-DE   Germany
Kineret
   Sheba Medical Center
      2012   Phase 3   NCT01705756   Israel
ONE additional blood sample during A planned blood test
   Hospices Civils de Lyon
      2021   -   NCT04478409   France
Probiotic
   Rambam Health Care Campus
      2013   -   NCT02021084   -
Rilonacept
   The Cleveland Clinic
      2008   Phase 2   NCT00582907   United States
RIST4721
   Aristea Therapeutics, Inc.
      2022   Phase 2   NCT05448391   Israel;Turkey
Roactemra® 20MG/ML konzentrat
   University Hospital Tuebingen
      2017   Phase 2   EUCTR2016-004505-13-DE   Germany
RPH-104
   R-Pharm International, LLC
      2021   Phase 2   NCT05190991   Armenia;Georgia;Russian Federation;Turkey
      2021   Phase 2   NCT05092776   Armenia;Georgia;Russian Federation;Turkey
Tocilizumab
   Department of Immunology and Rheumatology, Division of Advanced Preventive Medical Sciences, Nagasaki University Graduate School of Biomedical Sciences
      2018   -   JPRN-UMIN000032557   Japan
      2018   -   JPRN-UMIN000028010   Japan
   University Hospital Tuebingen
      2018   Phase 2   NCT03446209   Germany
Wheat flour
   University of Palermo
      2018   -   NCT03563300   Italy